Document Detail


Focus on ziprasidone: a review of its use in child and adolescent psychiatry.
MedLine Citation:
PMID:  19018327     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To review published literature regarding ziprasidone in child and adolescent psychiatry.
METHODS: A literature review was conducted using the medline search term: 'ziprasidone' with limits: Human trials, English language, All Child (Age 0-18). Additional articles were identified from reference information and poster presentation data.
RESULTS: Two randomized controlled trials and five prospective open-label studies have been conducted with ziprasidone. Additionally, several case reports and case series are reviewed. Ziprasidone has a greater propensity for QT(c) prolongation and risk for fatal arrhythmias compared to other atypical antipsychotics. Careful history taking regarding presence of congenital long QT syndrome is essential. Given limited clinical experience, electrocardiogram monitoring at baseline and following attainment of ziprasidone target dosage is warranted. No deaths from overdose have been reported in children and adolescents. Ziprasidone has a low potential for extrapyramidal side effects. Prolactin changes are small and transient. Lethargy, drowsiness, agitation and tachycardia were the most common adverse effects in randomized trials. Body weight changes with ziprasidone were comparable to placebo-treated subjects.
CONCLUSION: At present, ziprasidone should be considered a second or third-line option for a limited set of conditions. A role may exist for ziprasidone in patients who have experienced significant metabolic adverse effects with other atypical antipsychotics.
Authors:
Dean Elbe; Carlo G Carandang
Related Documents :
6694057 - Effects of severe daily events on mood.
11013627 - Fatal tumoural haemorrhage following decompressive craniectomy: a report of three cases.
19997697 - Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema.
9394947 - Case study: neuropsychiatric symptoms associated with the antimalarial agent mefloquine.
21524567 - Incomplete reporting of recruitment information in breast cancer trials published betwe...
16107867 - Epistaxis after pde-5 inhibitors misuse.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Académie canadienne de psychiatrie de l'enfant et de l'adolescent     Volume:  17     ISSN:  1719-8429     ISO Abbreviation:  J Can Acad Child Adolesc Psychiatry     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-11-21     Completed Date:  2010-06-29     Revised Date:  2013-05-23    
Medline Journal Info:
Nlm Unique ID:  101280868     Medline TA:  J Can Acad Child Adolesc Psychiatry     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  220-9     Citation Subset:  -    
Affiliation:
Department of Child and Adolescent Psychiatry, BC Children's Hospital, Vancouver, BC. delbe@cw.bc.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Models of substance use in adolescents with and without psychosis.
Next Document:  Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinas...